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ABSTRACT
Anti-mullerian hormone (AMH) is produced by the granular cells of primary, preantral and antral follicles. The circulating 
levels of AMH in adult women reflect the number of remaining primordial follicles. AMH determination plays an increasingly 
important role in diagnostics in endocrinology and gynecology in adult women. Although the determination of AMH levels 
is used in pediatric practice, still little is known about its role in various pubertal disorders in girls. This article presents the 
clinical use of AMH in girls and adolescents.
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INTRODUCTION
Anti-Müllerian Hormone (AMH), also known as the fac-
tor that inhibits the development of the Müllerian ducts, 
is a dimeric glycoprotein that belongs to the family of 
transforming growth factors β (TGFβ family) [1, 2], which 
has been predominantly known for its role in male sexual 
differentiation. The gene encoding AMH in humans is lo-
cated on chromosome 19 p13.3 and it contains five exons. 
The gene for the AMH receptor type 2 is located on chromo-
some 12p13. The biological action of AMH depends on bind-
ing to the specific AMH type II receptor (AMH-RII), which ex-
pression has been demonstrated in the mesenchymal cells 
surrounding the Müller ducts, in testes (Sertoli and Leydig 
cells), and in granular and TEIC cells of the ovary. The recep-
tor is a single transmembrane protein with serine- threonine 
kinase activity [2]. AMH expression and secretion are inhibit-
ed by androgens and estrogens, and in the situation of their 
deficiency or receptor defect also by gonadotrophins [1, 2].
Until about the fifth week of pregnancy (in the non-sex-
ually differentiated phase), both sexes have buds of both 
male and female genital structures, Wolff tubes and Müller 
tubes. In Y chromosome fetuses carrying the SRY gene, 
around seven weeks of gestation, testes begin to develop, 
and then Sertoli cells begin to secrete AMH, which causes 
the Müllerian ducts to overgrow. Leydig cells begin to pro-
duce testosterone, which is responsible for transforming the 
Wolff’s ducts into epididymis, seminal vesicles, ejaculatory 
ducts, and the abdominal part of the prostate. The external 
male genitalia develop under the influence of dihydrotes-
tosterone (DHT) [3, 4]. The maximum production of this 
hormone is observed between 12 and 16 weeks of gestation, 
which persists at a high level until reaching sexual maturity, 
then it significantly decreases in adult men [2]. In female 
fetuses, the lack of the SRY gene and the lack of AMH secre-
tion determine the differentiation of the Müllerian ducts, 
the atrophy of the Wolff ducts and the development of 
the female genital organs in the fetus. The Müllerian ducts 
properly develop into the fallopian tubes, uterus, cervix and 
the upper part of the vagina [3, 5]. In female fetuses, the 
production of AMH does not start until around 36 weeks 
of gestation, which is much later than the period of Muller-
ian duct sensitivity to AMH. 
AMH is produced by the granular cells of primary, pre-
antral, and early antral follicles. The highest concentration of 
AMH is shown by small antral follicles (2–4 mm in diameter). 
Even though the concentration of AMH in the blood is much 
lower than the concentration in the follicle, it correlates 
very well with it, which relates to usefulness in practice [6].
The role of AMH in adult women
AMH determination can be performed regardless of 
the phase of the menstrual cycle and the use of hormonal 
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contraception. AMH determination plays an increasingly 
important role in diagnostics in endocrinology and gyne-
cology in adult women [2, 4, 7–10]. With age, the number 
of ovarian follicles in a woman decreases, which translates 
into a decrease in AMH concentration in the blood (up to 
undetectable values after menopause), so the level of AMH 
reflects the aging process of the ovary [4]. Therefore, AMH is 
considered one of the best indicators of ovarian reserve, and 
therefore it is also considered a marker of the assessment 
of a woman’s reproductive potential [7, 9]. Reduced AMH 
concentrations are observed not only in the physiological 
aging of the ovary, but also in the premature ovarian fail-
ure (POF) [11]. There are also reports on the usefulness 
of monitoring AMH levels in predicting the age at which 
a woman will reach menopause [11]. Currently, many studies 
on the concentration of AMH concern its role in polycystic 
ovary syndrome (PCOS). The concentration of AMH was 
2–3 times higher in women suffering from PCOS than in 
women with ovaries with a normal number of follicles [10, 
11]. Research shows that AMH may also be a marker of hy-
perandrogenism in PCOS [10]. According to some reports, 
the concentration of AMH may also be useful in predicting 
the return of ovulatory cycles in obese women with PCOS 
after weight loss [2]. Although there is currently no clearly 
defined upper cut-off point of the AMH level, it is postulated 
to include this test in PCOS diagnostics.
Moreover, AMH may be a useful marker of granulosa-cell 
tumors (folliculoma) and their recurrence. In these clinical 
situations, AMH levels can be very high and correlate with 
tumor size [11].
The role of AMH in girls
After birth, in female infants, blood levels of AMH are 
very low (lower than in male fetuses), even undetectable. 
Research on the changes in AMH levels in the early stages 
of puberty is quite limited and reports remain inconsist-
ent. A few studies AMH levels rise during infancy and they 
are stable from childhood Hagen et al. conducted a study 
in which they tried to determine the individual concen-
tration of AMH in each of the examined girls. They found 
that circulating AMH shows only slight fluctuations during 
childhood and adolescence, and a random measurement of 
AMH appears to be representative. The negative AMH-FSH 
correlation in pre-pubertal girls supported the statement 
that AMH is a quantitative marker of ovarian follicles even 
in young girls. The mean AMH levels ranged between 5 and 
54 pmol/L. 10 girls had a mean AMH level below the cut-off 
of 8 pmol/L, of which four had not yet entered puberty. 
However, the relationship between the AMH level and the 
period since menarche has not been assessed [12, 13]. A later 
study by Hagen et al. shows that three years before the onset 
of puberty, AMH increases, while within two years after the 
beginning of puberty, AMH decreases by 30% [14]. 
The increased concentration of circulating AMH in the 
pre-pubertal period allowed for the recognition of the hor-
mone as a marker of ovarian follicle growth because its 
growth occurs in the period when the hypothalamic-pitui-
tary-ovary axis is still inactive [15]. Some statistical models 
suggest that the highest rate of recruitment of nongrowing 
follicles takes place between birth and 14 years of age which 
is an age of menarche in most girls [16]. 
Precocious puberty
The concentration of AMH may be a marker of the onset 
as well as the progression of sexual maturation in girls. Chen 
et al., in their study which comprised 83 girls with diagnosed 
central precocious puberty (CPP), found out that AMH and 
inhibin levels are potential biomarkers for distinguishing 
various progression rates in girls with CPP and they can assist 
in the distinction of progressive CPP and slowly progressive 
CPP at the time of diagnosis [17]. Also, Lashen et al. support 
the thesis that the rise of AMH and inhibin B levels in prepu-
bertal childhood may suggest the onset of central puberty 
[16]. Xue et al., in their study about AMH use in precocious 
puberty progression conclude, that although AMH may not 
be a good indicator for early diagnosis, it has significance 
in the auxiliary diagnosis, differential diagnosis, treatment 
and prognosis of sexual puberty disorders in children [18]. 
PCOS
AMH levels in adolescents have been also proved to 
have a clinical impact in young patients with PCOS. Kim 
et al. states that AMH may be a useful biomarker for the 
diagnosis of PCOS in obese girls, as AMH concentrations 
are twice higher in obese PCOS girls and correlate with 
hyperandrogenemia with the cut-ff point of 6.26 ng/mL 
[19]. Efthymiadou et al. proved that girls with premature 
adrenarche, especially those from mother with a history of 
PCOS, could have a higher risk of developing PCOS later in 
life, because they have increased serum AMH [20]. 
Premature ovarian insufficiency
Low or even undetectable level of AMH is a good marker 
of premature ovarian insufficiency (POI) in girls. At young 
age, POI occurs mostly in girls with Turner Syndrome and 
in girls receiving gonadotoxic treatment [21].
Granulosa cell tumors 
Although only a few percent of folliculomas are seen in 
girls in adolescents, we cannot forget about this pathology. 
Granulosa cell tumors may present as precocious puberty. 
High (masculine) levels of AMH in girls should be considered 
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a manifestation of ovarian pathology, however, we should 
not exclude ovarian tumor in girl with AMH levels within the 
reference range [21]. As mentioned previously, AMH may be 
an indicator of tumor recurrence. 
Determination of the presence of testicular 
tissue 
AMH concentrations within the male reference range 
are highly indicative of testicular tissue. Low or undetect-
able levels of AMH indicate either anorchia or dysgenetic 
testicular tissue or presence of ovarian tissue. This clinical 
implication is used when a child is born with bilaterally 
absent testes or ambiguous genitalia [21].
Other pathologies
Codner et al. conducted the study, which showed that 
AMH levels are increased in girls with type 1 diabetes (T1D) 
during childhood and decrease during puberty, which sug-
gests, that T1D modulates ovarian follicle growth differently 
once gonadotrophin levels rise. What is more, Codner et al. 
suggest, that girls with T1D exhibit similar endocrine findings 
to other groups at increased risk of developing PCOS [13].
Even though the literature provides information on the 
use of AMH in the diagnosis of many of the above-men-
tioned pathologies, the reference values of AMH concen-
tration in prepubertal and postmenarcheal girls are still 
poorly detailed. The knowledge of AMH norms in girls would 
enable further research on various types of pathologies 
occurring in them. AMH could become much more useful 
in the diagnosis of premature puberty, delayed puberty, 
thelarche praecox, menarche praecox, and the diagnosis 
of ovarian tumors in girls.
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